199 related articles for article (PubMed ID: 25535978)
1. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
2. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
3. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
4. [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph
Wu JH; Shi FF; Gong YP; Shi R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 48(2):216-220. PubMed ID: 28612529
[TBL] [Abstract][Full Text] [Related]
5. PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway.
Zhang Z; Zhang G; Kong C; Gong D
Mol Med Rep; 2016 Jan; 13(1):333-8. PubMed ID: 26548560
[TBL] [Abstract][Full Text] [Related]
6. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells.
Ono A; Oike R; Okuhashi Y; Takahashi Y; Itoh M; Nara N; Tohda S
Anticancer Res; 2013 Mar; 33(3):809-13. PubMed ID: 23482748
[TBL] [Abstract][Full Text] [Related]
8. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
9. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.
Hoang B; Benavides A; Shi Y; Yang Y; Frost P; Gera J; Lichtenstein A
J Biol Chem; 2012 Jun; 287(26):21796-805. PubMed ID: 22556409
[TBL] [Abstract][Full Text] [Related]
10. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
11. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
12. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.
Xing X; Zhang L; Wen X; Wang X; Cheng X; Du H; Hu Y; Li L; Dong B; Li Z; Ji J
Anticancer Drugs; 2014 Nov; 25(10):1129-40. PubMed ID: 25035961
[TBL] [Abstract][Full Text] [Related]
13. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line.
Yang X; Lin J; Gong Y; Ma H; Shuai X; Zhou R; Guo Y; Shan Q; He G
Hematol Oncol; 2012 Sep; 30(3):123-30. PubMed ID: 21898527
[TBL] [Abstract][Full Text] [Related]
14. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation.
Fournier MJ; Coudert L; Mellaoui S; Adjibade P; Gareau C; Côté MF; Sonenberg N; Gaudreault RC; Mazroui R
Mol Cell Biol; 2013 Jun; 33(11):2285-301. PubMed ID: 23547259
[TBL] [Abstract][Full Text] [Related]
16. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
17. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
18. mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
Gordeev SA; Bykova TV; Zubova SG; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
Oncotarget; 2015 Dec; 6(42):44905-26. PubMed ID: 26636543
[TBL] [Abstract][Full Text] [Related]
19. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
[TBL] [Abstract][Full Text] [Related]
20. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
